Clinical Trial Update: Sequencing Abiraterone and Enzalutamide in mCRPC [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating sequencing of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: COMPLETED